Image-guided radiotherapy for prostate cancer: A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging

William W. Wong, Steven E. Schild, Sujay A. Vora, Gary A. Ezzell, Ba D. Nguyen, Panol C. Ram, Michael C. Roarke

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate, in a prospective study, the use of 111In-capromab pendetide (ProstaScint) scan to guide the delivery of a concomitant boost to intraprostatic region showing increased uptake while treating the entire gland with intensity-modulated radiotherapy for localized prostate cancer. Methods and Materials: From September 2002 to November 2005, 71 patients were enrolled. Planning pelvic CT and 111In-capromab pendetide scan images were coregistered. The entire prostate gland received 75.6 Gy/42 fractions, whereas areas of increased uptake in 111In-capromab pendetide scan received 82 Gy. For patients with T3/T4 disease, or Gleason score ≥8, or prostate-specific antigen level >20 ng/mL, 12 months of adjuvant androgen deprivation therapy was given. In January 2005 the protocol was modified to give 6 months of androgen deprivation therapy to patients with a prostate-specific antigen level of 10-20 ng/mL or Gleason 7 disease. Results: Thirty-one patients had low-risk, 30 had intermediate-risk, and 10 had high-risk disease. With a median follow-up of 66 months, the 5-year biochemical control rates were 94% for the entire cohort and 97%, 93%, and 90% for low-, intermediate-, and high-risk groups, respectively. Maximum acute and late urinary toxicities were Grade 2 for 38 patients (54%) and 28 patients (39%) and Grade 3 for 1 and 3 patients (4%), respectively. One patient had Grade 4 hematuria. Maximum acute and late gastrointestinal toxicities were Grade 2 for 32 patients (45%) and 15 patients (21%), respectively. Most of the side effects improved with longer follow-up. Conclusion: Concomitant boost to areas showing increased uptake in 111In-capromab pendetide scan to 82 Gy using intensity-modulated radiotherapy while the entire prostate received 75.6 Gy was feasible and tolerable, with 94% biochemical control rate at 5 years.

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology Biology Physics
Volume81
Issue number4
DOIs
StatePublished - Nov 15 2011

Fingerprint

Image-Guided Radiotherapy
Indium
acceleration (physics)
indium
radiation therapy
Prostatic Neoplasms
cancer
grade
deprivation
Intensity-Modulated Radiotherapy
antigens
Prostate-Specific Antigen
toxicity
Androgens
Prostate
therapy
hematuria
prostate gland
Capromab Pendetide
glands

Keywords

  • Concomitant boost
  • External-beam radiotherapy
  • IGRT
  • IMRT
  • ProstaScint scan
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Image-guided radiotherapy for prostate cancer : A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. / Wong, William W.; Schild, Steven E.; Vora, Sujay A.; Ezzell, Gary A.; Nguyen, Ba D.; Ram, Panol C.; Roarke, Michael C.

In: International Journal of Radiation Oncology Biology Physics, Vol. 81, No. 4, 15.11.2011.

Research output: Contribution to journalArticle

Wong, William W. ; Schild, Steven E. ; Vora, Sujay A. ; Ezzell, Gary A. ; Nguyen, Ba D. ; Ram, Panol C. ; Roarke, Michael C. / Image-guided radiotherapy for prostate cancer : A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 81, No. 4.
@article{534153dc04e7475fa556f36dc8b54991,
title = "Image-guided radiotherapy for prostate cancer: A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging",
abstract = "Purpose: To evaluate, in a prospective study, the use of 111In-capromab pendetide (ProstaScint) scan to guide the delivery of a concomitant boost to intraprostatic region showing increased uptake while treating the entire gland with intensity-modulated radiotherapy for localized prostate cancer. Methods and Materials: From September 2002 to November 2005, 71 patients were enrolled. Planning pelvic CT and 111In-capromab pendetide scan images were coregistered. The entire prostate gland received 75.6 Gy/42 fractions, whereas areas of increased uptake in 111In-capromab pendetide scan received 82 Gy. For patients with T3/T4 disease, or Gleason score ≥8, or prostate-specific antigen level >20 ng/mL, 12 months of adjuvant androgen deprivation therapy was given. In January 2005 the protocol was modified to give 6 months of androgen deprivation therapy to patients with a prostate-specific antigen level of 10-20 ng/mL or Gleason 7 disease. Results: Thirty-one patients had low-risk, 30 had intermediate-risk, and 10 had high-risk disease. With a median follow-up of 66 months, the 5-year biochemical control rates were 94{\%} for the entire cohort and 97{\%}, 93{\%}, and 90{\%} for low-, intermediate-, and high-risk groups, respectively. Maximum acute and late urinary toxicities were Grade 2 for 38 patients (54{\%}) and 28 patients (39{\%}) and Grade 3 for 1 and 3 patients (4{\%}), respectively. One patient had Grade 4 hematuria. Maximum acute and late gastrointestinal toxicities were Grade 2 for 32 patients (45{\%}) and 15 patients (21{\%}), respectively. Most of the side effects improved with longer follow-up. Conclusion: Concomitant boost to areas showing increased uptake in 111In-capromab pendetide scan to 82 Gy using intensity-modulated radiotherapy while the entire prostate received 75.6 Gy was feasible and tolerable, with 94{\%} biochemical control rate at 5 years.",
keywords = "Concomitant boost, External-beam radiotherapy, IGRT, IMRT, ProstaScint scan, Prostate cancer",
author = "Wong, {William W.} and Schild, {Steven E.} and Vora, {Sujay A.} and Ezzell, {Gary A.} and Nguyen, {Ba D.} and Ram, {Panol C.} and Roarke, {Michael C.}",
year = "2011",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2011.01.048",
language = "English (US)",
volume = "81",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Image-guided radiotherapy for prostate cancer

T2 - A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging

AU - Wong, William W.

AU - Schild, Steven E.

AU - Vora, Sujay A.

AU - Ezzell, Gary A.

AU - Nguyen, Ba D.

AU - Ram, Panol C.

AU - Roarke, Michael C.

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Purpose: To evaluate, in a prospective study, the use of 111In-capromab pendetide (ProstaScint) scan to guide the delivery of a concomitant boost to intraprostatic region showing increased uptake while treating the entire gland with intensity-modulated radiotherapy for localized prostate cancer. Methods and Materials: From September 2002 to November 2005, 71 patients were enrolled. Planning pelvic CT and 111In-capromab pendetide scan images were coregistered. The entire prostate gland received 75.6 Gy/42 fractions, whereas areas of increased uptake in 111In-capromab pendetide scan received 82 Gy. For patients with T3/T4 disease, or Gleason score ≥8, or prostate-specific antigen level >20 ng/mL, 12 months of adjuvant androgen deprivation therapy was given. In January 2005 the protocol was modified to give 6 months of androgen deprivation therapy to patients with a prostate-specific antigen level of 10-20 ng/mL or Gleason 7 disease. Results: Thirty-one patients had low-risk, 30 had intermediate-risk, and 10 had high-risk disease. With a median follow-up of 66 months, the 5-year biochemical control rates were 94% for the entire cohort and 97%, 93%, and 90% for low-, intermediate-, and high-risk groups, respectively. Maximum acute and late urinary toxicities were Grade 2 for 38 patients (54%) and 28 patients (39%) and Grade 3 for 1 and 3 patients (4%), respectively. One patient had Grade 4 hematuria. Maximum acute and late gastrointestinal toxicities were Grade 2 for 32 patients (45%) and 15 patients (21%), respectively. Most of the side effects improved with longer follow-up. Conclusion: Concomitant boost to areas showing increased uptake in 111In-capromab pendetide scan to 82 Gy using intensity-modulated radiotherapy while the entire prostate received 75.6 Gy was feasible and tolerable, with 94% biochemical control rate at 5 years.

AB - Purpose: To evaluate, in a prospective study, the use of 111In-capromab pendetide (ProstaScint) scan to guide the delivery of a concomitant boost to intraprostatic region showing increased uptake while treating the entire gland with intensity-modulated radiotherapy for localized prostate cancer. Methods and Materials: From September 2002 to November 2005, 71 patients were enrolled. Planning pelvic CT and 111In-capromab pendetide scan images were coregistered. The entire prostate gland received 75.6 Gy/42 fractions, whereas areas of increased uptake in 111In-capromab pendetide scan received 82 Gy. For patients with T3/T4 disease, or Gleason score ≥8, or prostate-specific antigen level >20 ng/mL, 12 months of adjuvant androgen deprivation therapy was given. In January 2005 the protocol was modified to give 6 months of androgen deprivation therapy to patients with a prostate-specific antigen level of 10-20 ng/mL or Gleason 7 disease. Results: Thirty-one patients had low-risk, 30 had intermediate-risk, and 10 had high-risk disease. With a median follow-up of 66 months, the 5-year biochemical control rates were 94% for the entire cohort and 97%, 93%, and 90% for low-, intermediate-, and high-risk groups, respectively. Maximum acute and late urinary toxicities were Grade 2 for 38 patients (54%) and 28 patients (39%) and Grade 3 for 1 and 3 patients (4%), respectively. One patient had Grade 4 hematuria. Maximum acute and late gastrointestinal toxicities were Grade 2 for 32 patients (45%) and 15 patients (21%), respectively. Most of the side effects improved with longer follow-up. Conclusion: Concomitant boost to areas showing increased uptake in 111In-capromab pendetide scan to 82 Gy using intensity-modulated radiotherapy while the entire prostate received 75.6 Gy was feasible and tolerable, with 94% biochemical control rate at 5 years.

KW - Concomitant boost

KW - External-beam radiotherapy

KW - IGRT

KW - IMRT

KW - ProstaScint scan

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80255122686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80255122686&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.01.048

DO - 10.1016/j.ijrobp.2011.01.048

M3 - Article

C2 - 21477947

AN - SCOPUS:80255122686

VL - 81

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -